Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Tolerability of BIBV 308 SE Formulations
NCT02223000Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 1998
- Primary completion
- Jul 1998
01
Overview
Phase 1, randomised, open-label trial of dipyridamole in stroke and thromboembolism, sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve at steady state at 84 hours. Started Mar 1998; status: completed.
02
Drugs
dipyridamole
03
Conditions
strokethromboembolism
Beyond the preview
Go deeper on NCT02223000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223000.